Dallas, TX -- (SBWIRE) -- 11/14/2010 -- SandlerResearch announce Czech Republic Pharmaceuticals and Healthcare Report Q4 2010
Original Source: Pharmaceuticals and Healthcare Market
Buy Now: Market Research
In BMI’s Pharmaceuticals & Healthcare Business Environment Ratings for Q410, the Czech Republic has retained its top position and has extended its lead over second placed Poland. The long-term outlook for pharmaceutical sales has improved since Q310, mainly as a result of the healthier macroeconomic indicators. BMI has revised up the 2010 real GDP growth forecast to 2.7%, from 2.2% previously, as the Czech Republic continues to enjoy robust exports data on account of a improving German economy. The compound annual growth rate (CAGR) for Czech drug market expenditure now stands at 6.05% in local currency terms and 6.98% in US dollar terms between 2009 and 2014.
The combination of a concurrent high Rewards score, which positions the Czech Republic second only to Russia in this category, and a superior Risks score – behind only Slovenia and Estonia – are weighted and combined to deliver the Czech Republic’s top position in the Pharmaceuticals & Healthcare Business Environment Ratings for Q410.
The Czech Republic’s pharmaceutical market grew by 9.0% in local currency terms in 2009 to CZK79.16bn (US$4.16bn) at consumer prices. Based on the improved macroeconomic data and early figures from the State Institute for Drug Control (SÚKL), our Q410 forecast for 2010 drug expenditure has improved moderately to 7.1% growth to CZK84.80bn (US$4.30bn), compared to 6.2% growth forecast in the Q310 report.
Following the legislative election in May 2010, the outlook for healthcare and the potential for reforms were examined by BMI. The new centre-right coalition’s plans for the healthcare sector in the Czech Republic are generally favourable in terms of financial sustainability and the positive implications for the healthcare and pharmaceutical industries. However, BMI remains concerned that the strength of the healthcare reform programme is dependent on the delivery of a more comprehensive and exhaustive budget plan, as well as definitive actions to deliver the planned reforms.
Government departments face budget cuts of 10% from 2011 but the treasury has ring fenced health insurance contributions. Healthcare is viewed as a major priority for the government, with extensive reform programmes expected in the medical services sector and the pensions system. On the macroeconomic front, growth is expected to slow in 2011 as the government pursues fiscal austerity and export growth moderates. While we regard the government’s austerity drive as positive for the Czech Republic’s long-term macroeconomic stability, it will undoubtedly be a drag on headline growth due to lower government consumption and the depressing effect this will have on private consumption growth.
Browse complete report : Czech Republic Pharmaceuticals and Healthcare Report Q4 2010
Table Of Contents
Executive Summary 5
SWOT Analysis 6
Czech Republic Pharmaceuticals And Healthcare Industry SWOT 6
Czech Republic Political SWOT 7
Czech Republic Economic SWOT 8
Czech Republic Business Environment SWOT 8
Pharmaceutical Business Environment Ratings 9
Table: Emerging Europe Pharmaceuticals Business Environment Ratings, Q410 9
Rewards 10
Risks 10
Czech Republic – Market Summary 12
Regulatory Regime 13
Regulatory Developments 13
Pharmaceutical Advertising 14
Intellectual Property Environment 15
Pricing And Reimbursement Regime 16
Pricing And Reimbursement Developments 18
Table: Price Changes For Select Ratiopharm Products 19
Prescribing Rules 20
Industry Developments 22
Epidemiology 22
Healthcare Sector 23
Healthcare Sector Financing 23
Healthcare Insurance 24
Healthcare Reforms 25
Hospital Sector 28
Opposition To Health Fees 29
Pharmaceutical Wholesale 30
Pharmaceutical Retail 31
Table: Retail Pharmacy Market, 2000-2008 31
E-Pharmacies 32
Distance Selling Of Pharmaceuticals 34
Medical Devices 34
Industry Forecast Scenario 36
Overall Market Forecast 36
Key Growth Factors – Industry 38
Key Growth Factors – Macroeconomic 40
Table: Czech Republic Economic Activity, 2005-2014 41
Prescription Drug Market Forecast 42
Patented Product Market Forecast 44
Generic Drug Market Forecast 46
OTC Medicine Market Forecast 47
Medical Device Market Forecast 49
Pharmaceutical Trade Forecast 50
Other Healthcare Data Forecasts 51
Key Risks To BMI’s Forecast Scenario 52
Competitive Landscape 53
Pharmaceutical Sector 53
Company Developments 54
Research & Development Sector 56
Biotechnology 58
Company Monitor 59
Indigenous Companies 59
Zentiva (Sanofi-Aventis) 59
Walmark 62
Multinational Companies 65
AstraZeneca 65
Bristol-Myers Squibb 66
Sanofi-Aventis 67
Novartis 69
GlaxoSmithKline 70
Pfizer 72
Country Snapshot: Czech Republic Demographic Data 73
Section 1: Population 73
Table: Demographic Indicators, 2005-2030 73
Table: Rural/Urban Breakdown, 2005-2030 74
Section 2: Education And Healthcare 74
Table: Education, 2002-2005 74
Table: Vital Statistics, 2005-2030 74
Section 3: Labour Market And Spending Power 75
Table: Employment Indicators, 2001-2006 75
Table: Consumer Expenditure, 2000-2012 (US$) 75
Table: Average Annual Wages, 2000-2012 76
BMI Methodology 77
How We Generate Our Pharmaceutical Industry Forecasts 77
Risk/Reward Ratings Methodology 78
Ratings Overview 78
Table: Pharmaceutical Business Environment Indicators 79
Weighting 80
Table: Weighting Of Components 80
Sources 80
Forecast Tables 81
ABBREVIATIONS
Browse all : Pharmaceut Market
http://www.sandlerresearch.org/market-research/pharmaceuticals/
Browse all : Business Monitor International
http://www.sandlerresearch.org/publishers/business-monitor-international/
Browse all : Newly Published Market Research
http://www.sandlerresearch.org/LatestReport.aspx
Related Reports:
Czech Republic Commercial Banking Report Q4 2010
http://www.sandlerresearch.org/Reports/38182-czech-republic-commercial-banking-report-q4-2010.html
Czech Republic Oil and Gas Report Q4 2010
http://www.sandlerresearch.org/Reports/38183-czech-republic-oil-and-gas-report-q4-2010.html
Czech Republic Metals Report Q4 2010
http://www.sandlerresearch.org/Reports/37100-czech-republic-metals-report-q4-2010.html
Czech Republic Freight Transport Report Q4 2010
http://www.sandlerresearch.org/Reports/34413-czech-republic-freight-transport-report-q4-2010-q-q.html
Czech Republic Consumer Electronics Report Q4 2010
http://www.sandlerresearch.org/Reports/34289-czech-republic-consumer-electronics-report-q4-2010.html
About Sandler Research
Sandler Research houses a comprehensive online library of more than 10,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe.
Our client list boasts of many eminent publishers of such reports from across the world. As a third-party reseller of market research reports, we employ various marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques, in order to generate better revenues for our clients, entailing positive and robust results.
We also provide 24/7 online and offline support to our customers
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.sandlerresearch.org
Blog: http://sandlerresearch.blogspot.com/